The precision medicine approach is a process of systematically defeating an illness such as cancer. Cancer is the primary focus of various precision medicine initiatives.

Oncology precision medicine focuses on matching the most precise treatment to each cancer patient based on an individual's matching genetic profile, which could benefit them from the treatment offered.

Factors driving the market include an increase in cancer incidence globally, a decrease in trial and error-based medication prescription through pharmacogenomics, an increase in predictive biomarkers for cancer diagnosis, and accelerated technological breakthroughs in oncology precision medicine.

According to BIS Research, the global oncology precision medicine market was valued at $45.1742 billion in 2020 and is expected to reach $128.8916 billion by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.

Get your free sample report here

How Technological Advancements are Helping Precision Oncology Medicine

The following are approaches helping patients to fight their sufferings and get appropriate treatments:

The transition from low-throughput to high-throughput genomic sequencing: The introduction of sequencing technology has led to a better knowledge of genetic diseases since the technology can analyze many sections of the genome cost-effectively. Hence, it proved to be an efficient tool in examining genetic diseases.

Furthermore, the genetic data generated by sequencing has several applications, including diagnosing inherited disorders, finding biomarkers and genetic variables, and predicting response to medicines.

Single-cell precision detection vs. multicell hybrid detection: Traditional genetic testing is frequently based on mixed cell deoxyribonucleic acid (DNA) samples, making it hard to describe individual cell features in the sample or tissue. It interprets their intercellular distinctions with varied growth and development processes.

However, the recent breakthrough in single-cell sequencing technology has enabled the analysis of tumor heterogeneity and assisted in the study of clonal evolution.

This third-generation sequencing technology also helps to understand the spatial distribution characteristics of cancer cells. For example, in the case of breast cancer, it aids in characterizing breast cancer cells and different types of immune cells to visualize the cell distribution characteristics of different patients.

Building ctDNA detection technology applications: There are several clinical uses for the circulating tumor DNA technique employed in liquid biopsy.

It aids in early tumor identification, tumor therapy, methylation detection, and predicting tumor recurrence and metastasis, among other things.

Various test characteristics are utilized to predict various features of the disease. For example, computed tomography (ct)DNA technology is utilized to identify mutant allele fraction (MAF), which represents a tumor's burden.

It also aids in the detection of minimum residual disease (MRD) and hidden metastases, which aid in the monitoring of therapeutic efficacy.

In recent years, several detection technologies for ctDNA epidermal growth factor receptor (EGFR) mutations have been developed, including droplet digital polymerase chain reaction (DDPCR), amplification refractory mutation system (ARMS), and next-generation sequencing (NGS).

In comparison to histology detection, ctDNA-based multigene analyses such as microsatellite instability (MSI) assays and blood tumor mutational burden (BTM) demonstrate quick, convenient, and dynamic properties.

Technologies similar to ctDNA utilized in liquid biopsies will dynamically track tumor progression over time and aid future research of intratumor heterogeneity using a non-invasive blood sample.

Introduction of CRISPR technology: Clustered regularly interspaced short palindromic repeats (CRISPR) technology is a gene-editing tool that may be used to add, remove, or modify genes to treat various diseases by changing genetic information.

The technology has a lot of potential in oncology, and it's expected to be a good way to stop cancer from starting and progressing.

Through large-scale screening, the potential strategy has emerged as an effective way for identifying tumor-driving genes as biomarkers or therapeutic targets. This can help with issues such as drug resistance, poor selectivity, and recurrence.

To sum up, medical advancements are essential for society's progress. Precision medicine will almost certainly continue to be focused on developing new techniques and treatments for oncological diseases.